James George Chopas is VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 38,141 shares of APLS, which is worth approximately $1.1 Million. The most recent transaction as insider was on Sep 16, 2024, when has been sold 192 shares (Common Stock) at a price of $36.21 per share, resulting in proceeds of $6,952. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 38.1K
1.91% 3M change
16.71% 12M change
Total Value Held $1.1 Million

James George Chopas Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 16 2024
SELL
Open market or private sale
$6,952 $36.21 p/Share
192 Reduced 0.5%
38,141 Common Stock
Sep 03 2024
SELL
Open market or private sale
$21,719 $39.49 p/Share
550 Reduced 1.41%
38,333 Common Stock
Mar 15 2024
SELL
Open market or private sale
$10,388 $56.46 p/Share
184 Reduced 0.47%
38,883 Common Stock
Jan 22 2024
SELL
Open market or private sale
$68,965 $65.0 p/Share
1,061 Reduced 2.64%
39,067 Common Stock
Jan 16 2024
SELL
Open market or private sale
$57,723 $66.81 p/Share
864 Reduced 2.11%
40,128 Common Stock
Jan 16 2024
BUY
Grant, award, or other acquisition
-
8,312 Added 16.86%
40,992 Common Stock
Oct 23 2023
SELL
Open market or private sale
$6,077 $46.04 p/Share
132 Reduced 0.4%
32,680 Common Stock
Sep 14 2023
BUY
Grant, award, or other acquisition
-
2,500 Added 7.08%
32,812 Common Stock
Aug 31 2023
SELL
Open market or private sale
$22,717 $41.23 p/Share
551 Reduced 1.79%
30,312 Common Stock
Feb 21 2023
SELL
Payment of exercise price or tax liability
$19,539 $58.5 p/Share
334 Reduced 1.07%
30,863 Common Stock
Feb 21 2023
BUY
Grant, award, or other acquisition
-
4,044 Added 11.48%
31,197 Common Stock
Jan 20 2023
SELL
Payment of exercise price or tax liability
$47,833 $52.05 p/Share
919 Reduced 3.27%
27,153 Common Stock
Jan 12 2023
BUY
Grant, award, or other acquisition
-
9,621 Added 25.52%
28,072 Common Stock
Jan 12 2023
BUY
Grant, award, or other acquisition
-
9,621 Added 25.52%
28,072 Common Stock
Jan 12 2023
BUY
Grant, award, or other acquisition
-
9,621 Added 25.52%
28,072 Common Stock
Jan 12 2023
BUY
Grant, award, or other acquisition
-
9,621 Added 25.52%
28,072 Common Stock
Oct 20 2022
SELL
Payment of exercise price or tax liability
$7,540 $58.0 p/Share
130 Reduced 0.7%
18,451 Common Stock
Aug 30 2022
SELL
Payment of exercise price or tax liability
$32,833 $58.84 p/Share
558 Reduced 2.92%
18,581 Common Stock
Jan 21 2022
BUY
Grant, award, or other acquisition
-
6,974 Added 31.09%
15,456 Common Stock
Oct 20 2021
BUY
Grant, award, or other acquisition
-
882 Added 9.42%
8,482 Common Stock
Aug 30 2021
BUY
Grant, award, or other acquisition
-
7,600 Added 50.0%
7,600 Common Stock

Also insider at

RDUS
Radius Health, Inc. Healthcare
JGC

James George Chopas

VP/Chief Accounting Officer
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS